Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Bon Natural Life ( (BON) ) has shared an announcement.
On September 1, 2025, Bon Natural Life Limited’s subsidiary, Xi’an App-Chem Bio (Tech) Co., Ltd, entered into a significant Sales Cooperation Agreement with Beijing Huahai Keyuan Technology Co., Ltd. This agreement, valued at US$26 million, grants Huahai Keyuan the non-exclusive rights to distribute Bon’s second-generation tea pigment digestive health products across China for 36 months. This strategic partnership is expected to enhance Bon’s market presence in the rapidly growing digestive health sector and drive substantial revenue growth. The agreement underscores Bon’s commitment to leveraging its innovative tea pigment technology to expand its footprint in the global health market.
The most recent analyst rating on (BON) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bon Natural Life stock, see the BON Stock Forecast page.
Spark’s Take on BON Stock
According to Spark, TipRanks’ AI Analyst, BON is a Neutral.
Bon Natural Life’s overall stock score is primarily impacted by its challenging financial performance and bearish technical indicators. While the stock appears undervalued based on its P/E ratio, significant financial and operational challenges overshadow this potential opportunity.
To see Spark’s full report on BON stock, click here.
More about Bon Natural Life
Bon Natural Life Limited is a Cayman Islands company operating in the natural, health, and personal care industries. It is recognized as a leading bio-ingredient solution provider, focusing on innovative products such as tea pigment-based health solutions.
Average Trading Volume: 1,099,451
Technical Sentiment Signal: Sell
Current Market Cap: $12.72M
See more insights into BON stock on TipRanks’ Stock Analysis page.